Back to results
US 2017/0360702 A1Published application
Solid Solution Compositions and Use in Chronic Inflammation
AssigneeInfirst Healthcare Limited
InventorsRobin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
Life of this patent
Estimating the term…
Abstract
The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
Claims20
A solid solution pharmaceutical composition comprising:
- a) 25% to 31% by weight of an ibuprofen, or a pharmaceutically acceptable salt, solvate, or solvate of a salt thereof;
- b) 34% to 40% by weight of a hard fat that includes a triglyceride mixture;
- c) 22% to 28% by weight of a liquid lipid mixture that includes monoglyceride;
- and
- d) 7% to 13% by weight of a liquid glycol polymer.
2 more elements
A solid solution pharmaceutical composition comprising:
- a) 26% to 30% by weight of an ibuprofen, or a pharmaceutically acceptable salt, solvate, or solvate of a salt thereof;
- b) 35% to 39% by weight of a hard fat that includes a triglyceride mixture, the hard fat having a melting point of between 41° C. to 45° C.;
- c) 23% to 27% by weight of a liquid lipid that includes a monoglyceride;
- and
- d) 8% to 12% by weight of a liquid glycol polymer.
2 more elements
A solid solution pharmaceutical composition comprising:
- a) 27% to 29% by weight of an ibuprofen, or a pharmaceutically acceptable salt, solvate, or solvate of a salt thereof;
- b) 36% to 38% by weight of a hard fat that includes a triglyceride mixture, the hard fat having a melting point of between 41° C. to 45° C.;
- c) 24% to 26% by weight of a liquid lipid mixture that includes a monoglyceride;
- and
- d) 9% to 11% by weight of a liquid glycol polymer.
2 more elements
Dependencies are inferred from the claim text.